Crucell and DSM Announce PER.C6® Licensing Agreement with IQ Corporation for Production of Monoclonal Antibodies against Anthrax
Advertisement
Crucell N.V. and allied contract manufacturer DSM Biologics announced that they have signed a PER.C6® research license agreement with Dutch biotechnology company IQ Corporation. This license agreement allows IQ to evaluate and use the PER.C6® cell line for production of its monoclonal antibody portfolio.
IQ Corporation has opted to evaluate the PER.C6® cell line for use as a manufacturing platform for its proprietary anti-anthrax antibodies. Under the terms of the agreement, IQ will pay a signing fee and annual maintenance fees. Further financial details are not disclosed.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous